, Tracking Stock Market Picks
Enter Symbol:
Accelrys, Inc. (ACCL) [hlAlert]

up 90.99 %

Accelrys, Inc. (ACCL) upgraded to Buy with price target $7.50 by Dougherty & Company

Posted on: Friday,  Aug 6, 2010  11:25 AM ET by Dougherty & Company

Dougherty & Company rated Buy Accelrys, Inc. (NASDAQ: ACCL) on 08/06/2010, when the stock price was $6.55.
Since then, Accelrys, Inc. has gained 90.99% as of 04/29/2014's recent price of $12.51.
If you would have followed this Dougherty & Company 's recommendation on ACCL, you would have gained 90.99% of your investment in 1362 days.

Pharmacopeia is committed to discovering and developing novel therapeutics to address significant medical needs. The Company has a broad portfolio advancing toward clinical validation, both independently and with partners. Pharmacopeia's most advanced internal program is a dual-acting angiotensin and endothelin receptor antagonist for hypertension and diabetic kidney disease for which Phase 1 clinical trials are underway. Other internal proprietary programs address primarily immunoregulation. Pharmacopeia's collaborative efforts have resulted in a portfolio that includes one partnered program currently in Phase 2 clinical trials targeting chronic obstructive pulmonary disease and four partnered programs in Phase 1 clinical trials targeting rheumatoid arthritis, oncology, metabolic and inflammatory diseases. Four additional partnered compounds are in preclinical development.

Team The research group is composed of five senior analysts and two associate analysts. The senior analysts collectively have 44 years of securities industry experience, and include 3 MBA's, 2 CPA's, 2 PE's (professional engineer), a CFA and a CMA. The team has come together out of a passion for overlooked or misunderstood investment opportunities – generally in smaller-cap companies – and a love of in-depth research, with special emphasis on independent information sources and innovative thinking. Coverage Our research coverage is idea driven and balances the twin demands of opportunism for flexibility and universe consistency for maximization of information sources. Current sub-sectors of interest include: * Specialty retail * Internet security * Internet media * Auto-identification and data capture (AIDC & RFID) * Mobile computing * Specialty manufacturing * Chronic care management * Outpatient services * Medical devices * Healthcare IT
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/6/2010 11:25 AM Buy
6.55 7.50
as of 12/31/2010
1 Week down  -4.91 %
1 Month down  -1.07 %
3 Months up  19.39 %
1 YTD up  26.87 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/22/2008 1:25 PM Hold

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy